Final results of Australasian Gastrointestinal Trials Group ARCTIC study: An audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines

Annals of Oncology

Volumn 25, Issue 1, 2014, Pages 117-121

  Ransom, David ^a   Wilson, K ^b   Fournier, M ^b   Simes, R J ^b   Gebski, V ^b   Yip, D ^c   Tebbutt, N ^d   Karapetis, C S ^e   Ferry, D ^f   Gordon, S ^g   Price, T J ^h  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c The Australian National University   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e FLINDERS UNIVERSITY   (Australia)

^f ROYAL WOLVERHAMPTON HOSPITALS NHS TRUST   (United Kingdom)

^g Western Cardiology   (Australia)

^h UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Angina; Capecitabine; Cardiotoxicity; Fluoropyrimidine; Raltitrexed

Indexed keywords

CALCIUM ANTAGONIST; CAPECITABINE; CISPLATIN; DILTIAZEM; EPIRUBICIN; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; METOPROLOL; NITRIC ACID DERIVATIVE; OXALIPLATIN; RALTITREXED; TROPONIN;

ACUTE ABDOMEN; ADULT; AGED; ANGINA PECTORIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEART ARRHYTHMIA; HUMAN; INCIDENCE; MEDICAL AUDIT; MEDICAL RECORD REVIEW; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PAROXYSMAL DYSPNEA; PATIENT IDENTIFICATION; PERITONITIS; PRIORITY JOURNAL; RECTUM PERFORATION; RETROSPECTIVE STUDY; SIDE EFFECT; ST SEGMENT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SUPRAVENTRICULAR TACHYCARDIA; VERY ELDERLY;

ANGINA; CAPECITABINE; CARDIOTOXICITY; FLUOROPYRIMIDINE; RALTITREXED;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DRUG SUBSTITUTION; FLUOROURACIL; HEART DISEASES; HUMANS; MIDDLE AGED; QUINAZOLINES; THIOPHENES;

EID: 84899914048     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt479     Document Type: Article

References (24)

1. Kosmas C, Kallistratos MS, Kopterides P et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol 2008; 134: 75-82.
2. Jensen SA, Sorensen JB. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol 2006; 58: 487-493.
3. Shaib W, Lee V, Saif MW. Bolus 5-fluorouracil as an alternative modality to infusion 5-fluorouracil in a patient with rectal cancer and capecitabine-induced cardiotoxicity. In Vivo 2009; 23: 821-826.
4. Saif MW, Quinn MG, Thomas RR et al. Cardiac toxicity associated with capecitabine therapy. Acta Oncol 2003; 42: 342-344.
5. Jensen SA, Hasbak P, Mortensen J et al. Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle. J Clin Oncol 2010; 28: 5280-5286.
6. Becker K, Erckenbrecht JF, Haussinger D et al. Cardiotoxicity of the antiproliferative compound fluorouracil. Drugs 1999; 57: 475-484.
7. Saif MW, Shah MM, Shah AR. Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opin Drug Saf 2009; 8: 191-202.
8. Cunningham D, Zalcberg JR, Rath U et al. Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. 'Tomudex' Colorectal Cancer Study Group. Ann Oncol 1996; 7: 961-965.
9. Maughan TS, James RD, Kerr DJ et al. Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet 2002; 359: 1555-1563.
10. Kerr DJ. Clinical efficacy of 'Tomudex' (raltitrexed) in advanced colorectal cancer. Anticancer Drugs 1997; 8(Suppl 2): S11-S15.
11. Popov I, Carrato A, Sobrero A et al. Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1). Eur J Cancer 2008; 44: 2204-2211.
12. Kohne CH, Thuss-Patience P, Friedrich M et al. Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity. Br J Cancer 1998; 77: 973-977.
13. Paiva CE, Paiva BS, Garita R et al. Acute coronary syndrome associated with continuous 5-fluorouracil infusion in a patient with metastatic colorectal cancer-a case report with a discussion on this clinical dilemma. J Gastrointest Cancer 2009; 40: 133-137.
14. Stewart T, Pavlakis N, Ward M. Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina. Intern Med J 2010; 40: 303-307.
15. Tsibiribi P, Bui-Xuan C, Bui-Xuan B et al. Cardiac lesions induced by 5-fluorouracil in the rabbit. Hum Exp Toxicol 2006; 25: 305-309.
16. Alter P, Herzum M, Soufi M et al. Cardiotoxicity of 5-fluorouracil. Cardiovasc Hematol Agents Med Chem 2006; 4: 1-5.
17. Clarke SJ, Beale PJ, Rivory LP. Clinical and preclinical pharmacokinetics of raltitrexed. Clin Pharmacokinet 2000; 39: 429-443.
18. Wilson KS, Fitzgerald CA, Barnett JB et al. Adjuvant therapy with raltitrexed in patients with colorectal cancer intolerant of 5-fluorouracil: British Columbia Cancer Agency experience. Cancer Invest 2007; 25: 711-714.
19. Judson I, Maughan T, Beale P et al. Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex ZD1694). Br J Cancer 1998; 78: 1188-1193.
20. Clinical guidelines for administration of raltitrexed. Product monograph, Hospira, http://www.hospira.ca/english_docs/Tomudex_Eng_PM.pdf.
21. Zalcberg J. Overview of the tolerability of 'Tomudex' (raltitrexed): collective clinical experience in advanced colorectal cancer. Anticancer Drugs 1997; 8(Suppl 2): S17-S22.
22. Cocconi G, Cunningham D, Van Cutsem E et al. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. J Clin Oncol 1998; 16: 2943-2952.
23. Feliu J, Castanon C, Salud A et al. Phase II randomised trial of raltitrexedoxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer. Br J Cancer 2005; 93: 1230-1235.
24. Kelly C, Bhuva N, Harrison M et al. Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history. Eur J Cancer 2013; 49: 2303-2310.